These results illustrate how improving the tumor selectivity of a therapeutic anti-CD47 antibody while also promoting Fc-FcγR-mediated effector function can safely enhance antitumor efficacy in immunocompetent hosts. This evidence concerns the gene FCGR2A and neoplasm.